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Alternative splicing contributes to diverse aspects
of cancer pathogenesis including altered cellular
metabolism, but the specificity of the process or
its consequences are not well understood. We
characterized genome-wide alternative splicing
induced by the activating EGFRvIII mutation in
glioblastoma (GBM). EGFRvIII upregulates the
heterogeneous nuclear ribonucleoprotein (hnRNP)
A1 splicing factor, promoting glycolytic gene
expression and conferring significantly shorter sur-
vival in patients. HnRNPA1 promotes splicing of a
transcript encoding the Myc-interacting partner
Max, generating Delta Max, an enhancer of Myc-
dependent transformation. Delta Max, but not
full-length Max, rescues Myc-dependent glycolytic
gene expression upon induced EGFRvIII loss, and
correlates with hnRNPA1 expression and down-
stream Myc-dependent gene transcription in pa-
tients. Finally, Delta Max is shown to promote
glioma cell proliferation in vitro and augment
EGFRvIII expressing GBM growth in vivo. These
results demonstrate an important role for alterna-
tive splicing in GBM and identify Delta Max as1000 Cell Metabolism 17, 1000–1008, June 4, 2013 ª2013 Elsevier Ina mediator of Myc-dependent tumor cell meta-
bolism.
INTRODUCTION
Through alternative splicing, cancer cells preferentially express
transcripts whose protein products suppress apoptosis, activate
proliferative signaling pathways, and reprogram cellular meta-
bolism (David et al., 2010; Clower et al., 2010). The effect of spe-
cific oncogenes on genome-wide alternative splicing, how
alternative splicing is regulated through splicing factors, and
the functional consequences of splice variants for human cancer
are not well understood.
Here, we explore the role of alternative splicing in glioblastoma
(GBM), the most common and highly lethal form of adult brain
cancer. GBMs are highly glycolytic and contain mutations in
growth-factor-receptor-initiated signaling pathways, most
commonly the epidermal growth factor receptor (EGFR). EGFR
is amplified in nearly 50% of patients, often in association with
the constitutively activated mutant, EGFRvIII (Cancer Genome
Atlas Research Network, 2008; Parsons et al., 2008). EGFRvIII
induces major shifts in GBM cell metabolism (Guo et al.,
2009a); however, the contribution of alternative splicing to these
metabolic shifts is not currently known. We performed an unbi-
ased analysis of EGFRvIII-dependent genome-wide splicing
coupled to mechanistic studies in cell lines, xenotransplants,c.
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Figure 1. EGFRvIII Enhances Alternative Splicing, Induces Expression of Myc Target Genes, and Promotes Glucose Uptake In Vivo
(A) Schematic illustration of experimental design used to coordinately analyze gene expression and alternative splicing promoted by EGFRvIII in vivo.
(B) Heatmap of expression for genes in the indicated gene sets (EGF-Pathway and Myc). Gene expression in U87 and U87-EGFRvIII tumors from three mice is
shown.
(C) Schematic showing increased expression of Myc-regulated genes in EGFRvIII-expressing tumors. The fold upregulation of these transcripts in EGFRvIII
expressing tumors is shown in green.
(D) MicroPET/CT imaging comparing U87 with U87-EGFRvIII xenograft tumors (arrow). The graph represents FDG uptake averaged for three tumors (white-
dotted circles) presented as percentage injected dose per gram (%ID/G) (p value by t test).
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EGFR Mutation-Induced Alternative Splicing of Maxand clinical samples, andwe report here identification of amech-
anism of metabolic reprogramming and tumor growth through
alternative splicing of the Myc-interacting protein Max.
RESULTS AND DISCUSSION
EGFRvIII Induces Genome-wide Changes in Alternative
Pre-mRNA Splicing and Promotes Altered Metabolism
To identify EGFRvIII-dependent alternative splicing, we overex-
pressed the EGFRvIII mutant in the U87 glioma cell line. We
isolated and analyzed mRNA from U87 and U87-EGFRvIII ex-
pressing xenografts using Affymetrix Human Research Junction
Arrays (Figure 1A). MADS+ bioinformatic analysis (Shen et al.,
2010) revealed alternative splicing changes for 298 cassette
exons (see Table S1 online). Gene ontology (GO) enrichment
analysis of differentially spliced transcripts revealed significantly
enhanced representation of transcripts encoding proteins
involved in transcription/translation (Figure S1). In addition,Cellgene expression analysis of the arrays identified not only upregu-
lation of EGF-pathway target genes as expected, but also
showed upregulation of multiple Myc target genes, including
Glucose Transporter 1 (GLUT1) and GLUT3, Hexokinase2
(HK2), and Pyruvate Dehydrogenase Kinase (PDK1) (Figures 1B
and 1C). These data suggested altered cellular metabolism in
EGFRvIII-expressing tumors. In fact, EGFRvIII-expressing
tumors of the same size as their isogenic counterparts took up
nearly twice as much 18F-FDG-labeled glucose, confirming an
enhanced glycolytic phenotype consistent with their growth
advantage as xenografts (Guo et al., 2009a, 2009b, 2011; Furnari
et al., 2007) (Figure 1D).
HnRNPA1 Splicing Factor Downstream of EGFRvIII
Regulates Glycolytic Gene Expression
Alternative splicing of transcripts encoding glycolytic enzymes,
including the pyruvate kinase isoform PKM2 (Christofk et al.,
2008a, 2008b), are mediated at least in part by theMetabolism 17, 1000–1008, June 4, 2013 ª2013 Elsevier Inc. 1001
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Figure 2. EGFRvIII Regulates Expression of Myc and hnRNPA1 Splicing Factor, Promoting Glycolysis, Proliferation, and Shorter Patient
Survival
(A) Immunoblot analysis of Myc and downstream splicing factors from three U87 xenograft tumor lysates and three U87-EGFRvIII xenograft tumor lysates.
Numerical values below HnRNPA1 and Myc blots (black arrows) are densitometric quantification of bands normalized to tubulin.
(B) (Left) Immunoblot analysis of lysates fromU373with doxycycline-regulated EGFRvIII expression, and (right) relative mRNA transcript levels of GLUT1, GLUT3,
HK2, and PDK1 upon acute loss of EGFRvIII (n = 4; shown is the mean ± SD; *p < 0.05).
(C) Immunoblot analysis of patient GBM biopsy samples having low EGFR expression or EGFR amplification and EGFRvIII expression.
(D) Kaplan-Meier overall survival plots of 131 primary GBM patients stratified by survival plots for hnRNPA1 expression. The single p value is based on the
difference of the two curves and was calculated using the log rank test.
(E) Cell proliferation of U87-EGFRvIII cells with hnRNPA1 knockdown (n = 3; shown is mean ± SD; **p < 0.01).
(F) Uptake of fluorescein-conjugated glucose (2NBDG) after 1 hr in U87-EGFRvIII cells transfected with the indicated siRNA. Unstained cells are without 2NBDG.
(G) Real-time qPCR analysis for glycolytic gene expression in U87-EGFRvIII cells with hnRNPA1 knockdowns (n = 3; shown is mean ± SD; *p < 0.05).
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EGFR Mutation-Induced Alternative Splicing of Maxheterogeneous nuclear ribonuclear proteins (hnRNPs) A1 and
A2, as well as by polypyrimidine tract binding protein (PTB) (Da-
vid et al., 2010; Clower et al., 2010; Sun et al., 2011). HnRNPA1
expression was increased in EGFRvIII-expressing xenografts,
whereas no consistent differences in hnRNPA2 or PTB isoform
4 were detected, although there was a small change in PTB
isoform 1 expression (Figure 2A). Therefore, we focused on the
potential role of hnRNPA1 in mediating the EGFRvIII-splicing-
associated changes in glycolysis.
To examine the effect of EGFRvIII on hnRNPA1 expression in
the acute setting, we analyzed U373 GBM cells expressing1002 Cell Metabolism 17, 1000–1008, June 4, 2013 ª2013 Elsevier InEGFRvIII under a doxycycline-regulated promoter (tet-off) (Mu-
kasa et al., 2010). Myc and hnRNPA1 levels were tightly linked
to those of EGFRvIII (Figures 2A and 2B). Induced loss of
EGFRvIII in an acute setting resulted in reduced hnRNPA1 and
decreased expression of glycolytic genes GLUT1, GLUT3,
HK2, and PDK1 (Figure 2B). Importantly, in tumor lysates ob-
tained from GBM patients, hnRNPA1 expression levels corre-
lated with those of EGFRvIII expression (Figure 2C). To assess
clinical relevance for these findings, we determined the correla-
tion between hnRNPA1 expression and GBM patient survival.
Stratification of 131 primary GBM patients from the UCLA brainc.
Cell Metabolism
EGFR Mutation-Induced Alternative Splicing of Maxtumor gene expression database (http://www.probesetanalyzer.
com/) by hnRNPA1 gene expression levels revealed a highly sig-
nificant correlation between elevated hnRNPA1 expression and
short overall survival (p = 0.0028) (Figure 2D). Taken together,
these results place the splicing factor hnRNPA1 downstream
of EGFRvIII in GBM and demonstrate that high levels of
hnRNPA1 expression are associated with aggressive tumors in
brain cancer patients.
Pharmacological inhibition of mTOR downstream of
EGFRvIII, or combined inhibition of EGFRvIII and the MAPK
pathway, inhibited hnRNPA1 expression in glioma cells (Figures
S2A–S2C). Genetic inhibition of mTOR complex 1 and mTOR
complex 2 by siRNA knockdown of raptor and rictor alone, or
in combination, further confirmed the mTOR dependence on
the induction of hnRNPA1, consistent with previous findings
(Sun et al., 2011) (Figure S2B). We then examined the functional
impact of hnRNPA1 on cell proliferation, glucose uptake, and
glycolytic gene expression. Two independent hnRNPA1 knock-
down constructs significantly inhibited cell proliferation (Fig-
ure 2E). Surprisingly, loss of hnRNPA1 inhibited glucose uptake
(Figure 2F), which was accompanied by decreased expres-
sion of glycolytic genes GLUT1, GLUT3, HK2, and PDK1
(Figure 2G).
HnRNPA1 Promotes Splicing of the Transcript Encoding
Myc-Binding Partner Max
We then searched for potential hnRNPA1-dependent alterna-
tively spliced transcripts involved in EGFRvIII pathogenesis.
Bioinformatic analysis identified 40 differentially spliced exons
with optimal hnRNPA1 binding sites (UAGGGA/U) within
200 bp upstream or downstream of the exon. Among the
top ‘‘hits,’’ we identified an alternatively spliced form of the
Myc-interacting protein Max, an obligate heterodimeric
c-Myc binding partner that regulates Myc function (Blackwood
and Eisenman, 1991; Hurlin and Huang, 2006). The intronic re-
gion upstream of exon 5 of Max contains a potential
hnRNPA1-binding site that is highly conserved, suggesting
evolutionary significance (Figure S3A). Inclusion of exon 5 gen-
erates a truncated Max protein referred to as Delta Max
(Ma¨kela¨ et al., 1992; Va¨strik et al., 1993; Hirvonen et al.,
1994) (Figures S3B and S3C). Although Delta Max was previ-
ously shown to augment Myc- and Ras-dependent transfor-
mation, its function in human cancer has not been established
(Ma¨kela¨ et al., 1992). To obtain direct evidence for a physical
association between hnRNPA1 and the intronic region up-
stream of exon 5 of Max, we performed crosslinking and
immunoprecipitation (CLIP) assay. The intronic region
harboring the potential hnRNPA1 binding site was immunopre-
cipitated with hnRNPA1 (Figure 3A). In patient-derived GBM
neurospheres, the extent of exon 5 inclusion was tightly linked
to the level of hnRNPA1 expression (Figure 3B). We then
determined whether hnRNPA1 could mediate alternative
splicing of Max to yield the Delta Max transcript and protein.
HnRNPA1 knockdown significantly decreased Delta Max
mRNA and protein expression in GBM cells (Figures 3C and
3D). We confirmed Delta Max expression in a panel of GBM
tumor lysates, in association with EGFRvIII (Figure 3E). Taken
together, these results suggest that EGFRvIII promotes Delta
Max splicing through hnRNPA1.CellDelta Max Promotes Glycolytic Gene Expression and
Contributes to EGFRvIII-Mediated GBM Tumor Growth
Delta Max is predicted to mediate its effects through Myc
(Ma¨kela¨ et al., 1992), which regulates the growth and prolifera-
tion of cancer cells at least in part by increasing the uptake
and metabolism of glucose (Dang, 2011, 2012). Therefore, we
sought to determine whether Delta Max could promote GBM
cell proliferation, whether it required the presence of glucose,
whether it was Myc dependent, and whether it was specific to
this alternatively spliced form of Max. Overexpression of Delta
Max, but not wild-type Max, increased GBM cell proliferation
in glucose-containing media but not galactose-containing me-
dia, suggesting that the effect on proliferation is glucose depen-
dent and that it is specific for the alternatively spliced form of
Max (Figure 4A). Concomitantly, Delta Max, but not wild-type
Max, increased the expression of the glucose transporter
GLUT3 and HK2 in U87 glioma cells, which was abrogated by
Myc knockdown (Figures S4A and S4B). Taken together, these
results indicated that Delta Max promotes glycolytic gene
expression in a Myc-dependent fashion.
To determine whether EGFRvIII mediates GBM cell prolifera-
tion through Delta Max-dependent effects on glycolytic meta-
bolism, we examined the impact of Delta Max on glycolytic
gene expression in U373 GBM cells in which EGFRvIII is under
the control of a doxycycline-regulated promoter (tet-off) (Mukasa
et al., 2010). Silencing of EGFRvIII suppressed the expression of
glycolytic genes GLUT1, GLUT3, HK2, and PDK1, consistent
with its known effect on promoting glycolytic metabolism (Guo
et al., 2009a). Importantly, overexpression of Delta Max, but
not wild-type Max, maintained glycolytic gene expression in
the absence of EGFRvIII signaling (Figure 4B). These results sug-
gest an epistatic relationship by which EGFRvIII regulates GBM
cell glycolysis through Delta Max. The inability of wild-type Max
to rescue glycolytic gene expression (Figure 4B) and to promote
GBM growth in glucose-containing media (Figure 4A) demon-
strates that alternative splicing of Max to Delta Max is required
to promote glucose-dependent GBM cell proliferation.
To determine whether Delta Max was required for the growth
of EGFRvIII-expressing GBMs, we examined the effect of Delta
Max depletion on tumor growth in vivo. Genetic depletion of
Delta Max resulted in a nearly 5-fold reduction in tumor size rela-
tive to control, p < 0.01 (Figure 4C). Consistent with the demon-
strated effect of Delta Max on glycolytic gene expression (Fig-
ure 4B), siRNA-mediated depletion of Delta Max specifically
inhibited GLUT1, GLUT3, HK2, and PDK1 gene expression (Fig-
ure S4C), and also reduced glucose consumption and lactate
production, two readouts of aerobic glycolysis (Figure 4D and
Figure S4D). Overexpression of the si-resistant Delta Max
construct fully rescued the effect of the knockdown, confirming
the specificity of the siRNA targeting Delta Max (Figure S4D).
Myc has previously been shown to transcriptionally upregulate
hnRNPA1 levels (David et al., 2010), raising the possibility of a
‘‘feedforward’’ loop. Indeed, overexpression of Delta Max
increased hnRNPA1 transcript levels, which was abrogated by
Myc siRNA knockdown (Figure S4E). Taken together, these re-
sults suggest a feedforward regulatory loop in which EGFRvIII,
through mTOR-dependent upregulation of Myc and splicing of
Delta Max, feeds back to further elevate hnRNAP1 through
Myc-dependent transcriptional regulation (Figure 4E).Metabolism 17, 1000–1008, June 4, 2013 ª2013 Elsevier Inc. 1003
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(A) Real-time PCR for Max intron upstream of exon 5 using RNA extracted from hnRNPA1 immunoprecipitated from U87-EGFRvIII cells after UV crosslinking
(CLIP) as described in the Supplemental Experimental Procedures.
(B) Real-time PCR splicing analysis for Max exon 5 and immunoblot analysis for hnRNPA1 in neurospheres established from patient GBM biopsies.
(C) Real-time PCR splicing analysis for Max exon 5 in hnRNPA1 knockdown cells from Figure 2E.
(D) Max immunoblot of lysates from U87-EGFRvIII cells transfected with siRNAs to hnRNPA1.
(E) Immunoblot for Max in Patient GBM biopsies from Figure 2C.
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EGFR Mutation-Induced Alternative Splicing of MaxGlycolytic Gene Expression in Brain Cancers Correlates
with EGFRvIII and hnRNPA1
Finally, to assess clinical relevance of our findings, we examined
the correlation between EGFRvIII expression and hnRNPA1
levels, and between hnRNPA1 and Myc-regulated glycolytic
target gene expression in the 120 classical, mesenchymal, and
neural GBMs analyzed in the Cancer Genome Atlas (TCGA)
data from the Unified Scaled data set (Verhaak et al., 2010).
HnRNPA1 expression was significantly elevated in EGFRvIII-
positive GBMs (p = 0.00881) (Table S2). Further, downstream
glycolytic genes were significantly correlated with hnRNPA1 in
these clinical samples (Table S3). Most importantly, like
hnRNAP1, high-level expression of the glycolytic genes
GLUT1, GLUT3, HK2, and PDK1 correlated with short overall
survival of GBM patients (Figure S4F). Taken together, these re-
sults provide clinical evidence that the hnRNPA1-dependent
glycolytic pathway confers more biologically aggressive
behavior in patients.
Delta Max was identified nearly 20 years ago, when it was re-
ported to augment Myc-dependent transformation (Ma¨kela¨
et al., 1992; Va¨strik et al., 1993; Hirvonen et al., 1994). However,
it was lost from scientific discourse relatively soon thereafter, for1004 Cell Metabolism 17, 1000–1008, June 4, 2013 ª2013 Elsevier Inlack of apparent relevance in human cancer. We now demon-
strate a clinically important role for Delta Max in mediating the
intersection of a key oncogenic signaling pathway with a meta-
bolic transformation that promotesGBMprogression (Figure 4E).
Myc integrates cellular proliferation with metabolism in many
cancers (Vander Heiden et al., 2009; Koppenol et al., 2011; Lev-
ine and Puzio-Kuter, 2010; DeBerardinis et al., 2008) but is
amplified or mutated in only a subset. These results provide an
alternative splicing-dependent mechanism, in addition to regu-
lating Myc levels (Gan et al., 2010), by which GBMs lacking
Myc amplification or mutation engage Myc signaling to regulate
tumor metabolism.EXPERIMENTAL PROCEDURES
Cell Culture and Transfections
U87-EGFRvIII, U87, and U373-EGFRvIII glioma cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Cellgro) supplemented with
10% fetal bovine serum (FBS; Omega Scientific), 1% penicillin/strepto-
mycin/glutamine (Invitrogen), and cells were incubated at 5% CO2 at 37
C.
Transfection for overexpression was performed using FuGene6 (Roche) ac-
cording to the manufacturer’s instructions. Delta Max, wild-type Max, and
Flag-tagged Delta Max constructs were in vector pDream 2.1 and synthesizedc.
Cell Metabolism
EGFR Mutation-Induced Alternative Splicing of Maxby GenScript USA Inc. Doxycycline induction of U373-EGFRvIII cells was also
as described previously (Mukasa et al., 2010).
Xenograft Tumor Studies
Isogenic human glioma cells U87 and U87-EGFRvIII were implanted subcuta-
neously (s.c.) into immunodeficient SCID/Beige mice. SCID/Beige mice were
housed and maintained in compliance with the regulations of the Division of
Laboratory Animal Medicine of the University of California, Los Angeles
(UCLA). U87 and U87-EGFRvIII cell lines were resuspended at 13 106 cells/ml
in PBS with Matrigel (BD) and were implanted s.c. on opposite sides of the
mouse abdomen. All procedures were approved by an Institutional Review
Board (IRB) at UCLA. For MicroPET/CT imaging U87 and U87-EGFRvIII cells
were implanted s.c. in the abdomen of separate mice. MicroPET/CT scanning
and analysis were performed as previously described (Guo et al., 2009a).
Microarray and Survival Data Analysis
Human Research Junction Arrays (Affymetrix) were used to identify differen-
tially expressed and spliced transcripts between U87 and U87-EGFRvIII xeno-
graft tumors from NOD/SCID/gamma (NSG) mice. RNA was isolated from
xenograft tumors with Trizol (Invitrogen). For microarray analysis, RNA was
DNase (Ambion) treated and amplified using the WT Expression Kit (Ambion)
and WT Terminal Labeling kit (Affymetrix). Human Research Junction Arrays
were obtained from Affymetrix, and labeled samples were hybridized and
scanned in the UCLA DNA Microarray Facility. Gene expression and alterna-
tive splicing were analyzed with MADS+ software (Shen et al., 2010). Heat-
maps were generated using Gene Set Enrichment Analysis (GSEA) software
(Mootha et al., 2003; Subramanian et al., 2005).
Survival Data and Gene Correlation Data in Clinical Samples
These microarray data are from the TCGA and were downloaded from the
Cancer Cell publication ‘‘An integrated genomic analysis identifies clinically
relevant subtypes of GBM characterized by abnormalities in PDGFRA,
IDH1, EGFR and NF1,’’ at https://tcga-data.nci.nih.gov/docs/publications/
gbm_exp/unifiedScaled.txt. Survival curves for the UCLA data are publicly
available through the following website: http://probesetanalyzer.com/.
Alternative Splicing Analysis
Alternative splicing was assayed using semiquantitative reverse-transcriptase
PCR. Primers were designed to constitutive exons flanking alternative exons
of interest. Primers were as follows: MAX_(85)_F 50-TCAGTCCCATCACTC
CAAGG-30, and MAX_(85)_R 50-GCACTTGACCTCGCCTTCT-30. Reverse
primers were 32P end labeled, and 22 cycle PCR reactions were resolved by
denaturing PAGE. Radioactive signal was detected using a Typhoon Phos-
phorimager (GE) and quantified with ImageQuant TL software (Amersham
Biosciences).
Real-Time Quantitative PCR
Total RNA was extracted with Trizol (Invitrogen) followed by DNase treatment
(Ambion) and Proteinase K treatment (Roche) according to the manufacturer’s
instructions. For cDNA synthesis, 500 ng of RNA was used with SuperScript
VILO cDNA Synthesis kit (Invitrogen), and 1 ml of this used with iQ SYBR Green
Supermix (Bio-Rad) for quantitative real-time PCR. Primers were synthesized
by IDT and were designed (using Primer3) to amplify approximately 200 bp of
the 30UTR region of targets. Sequence of the primers is provided in the Supple-
mental Information. Real-time PCR was performed in triplicate using Bio-Rad
iCycler iQ Real-Time PCR Detection System. Analysis was using the iCycler iQ
Optical SystemSoftware (Version 3.0a) and data normalized to vinculin internal
control.
Glucose Uptake Assay
Cells were grown in a 6-well plate in DMEM with 0.5% FBS without antibiotics
for 24 hr, and media was replaced with DMEM containing 10% FBS (no anti-
biotics) and 100 mM 2-NBDG (Invitrogen). Cells were incubated for 1 hr at
37C 5% CO2 incubator, washed three times with PBS followed by lifting
with trypsin, washed, and analyzed by subsequent flow cytometric analysis
using FACSCalibur Analyzer (BD).CellCell Proliferation Assays
Cells were transfected with siRNA and 24 hr later seeded in a 96-well plate with
DMEM containing 0.5% FBS. Relative growth rate was determined after 72 hr
using Cell Proliferation Assay Kit (Millipore). Cells were incubated 30 min at
37C 5% CO2 incubator after adding tetrazolium salt WST-1 (Millipore) and
the absorbance measured using a microplate reader (Bio-Rad) at 420–
480 nm. For determining cell number, cells were transfected with siRNA in a
6-well plate and 24 hr later were washed and replaced with DMEM supple-
mented with 0.5% FBS. After 48 and 72 hr, cells were counted with a haemo-
cytometer. For proliferation on glucose- and galactose-containingmedia, cells
were placed in 96-well plates at 2.53 103 cells/well in 100 ml of growthmedium
and incubated in each condition of treatment. For the measurement of
glucose-dependent proliferation, DMEM containing glucose (Cellgro) or no-
glucose DMEM (GIBCO) supplemented with 4.5 g/l Galactose (Sigma) was
used as previously reported (Finley et al., 2011). Cell proliferation was exam-
ined with Cell Proliferation Assay Kit (Millpore) according to the manufacturer’s
instructions. The absorbance of the treated and untreated cells was measured
with a microplate reader (Bio-Rad) at 420–480nm. Data represent the mean ±
SD of four independent experiments.
Antibodies, Cell Lysate Preparation, and Immunoblotting
Specific antibodies were purchased from the following commercial sources:
anti-Max antibody was rabbit polyclonal from Abcam (ab68578); anti-
HnRNPA1 was mouse monoclonal from Sigma (clone 9H10); anti-EGFR/
EGFRvIII cocktail antibody was from Upstate; anti-actin was from Novus
Biologicals (AC-15); anti-tubulin was mouse monoclonal (T4026) from Sigma;
anti-Myc (D84C12), anti-HnRNPA2 (2A2), anti-phosphoEGFR (Y1068), anti-
HA (6E2), anti-phosphoAkt (S473), anti-Akt, anti-rS6, anti-phospho-rS6
(S235/S236), anti-phosphop44/42 MAPK (ERK1/2), anti-rictor, and anti-raptor
were from Cell Signaling; anti-PTB was provided by D.L. Black. For cell lysate
preparation, cells were washed with PBS and lysed with RIPA lysis buffer
(50 mM Tris-HCL [pH 7.4], 150 mM NaCl, 0.5% deoxycholate, 1% Nonidet
P-40, and 0.1% SDS) (Boston BioProducts) containing half protease inhibitor
cocktail (Thermo Scientific) and half phosphatase inhibitor cocktail (Thermo
Scientific). Protein concentration of lysates was determined using the
Bradford assay kit (Bio-Rad). Protein electrophoresis was with 12% NuPAGE
Bis-Tris precast Mini gels (Invitrogen) with MES running buffer (Invitrogen),
immunoblotting was according to antibody supplier instructions, and western
blot detection was using SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific). For detection of both Myc and Max, SuperSignal West
Femto Chemiluminescent Substrate (Thermo Scientific) was used. ImageJ
analysis software (NIH) was used for densitometric quantification of
imunoblots.
Patient GBM Biopsy Samples and Neurosphere Culture
Patient GBM samples were collected following surgical resection at UCLA.
GBM samples were provided, with patient consent for tissue acquisition as
per an IRB-approved protocol, by the Brain Tumor Translational Resource
(BTTR) at UCLA. Neurospheres were isolated and cultured as previously
described (Nakano and Kornblum, 2009).
RNAi Experiments and Inhibitor Studies
Transfections of siRNA were performed by using Lipofectamine RNAiMAX (In-
vitrogen) according to the manufacturer’s instructions. The siRNA targeting
exon 5 of Delta Max (target sequence CAUGGAAGAUGCAAGUAAA) was pur-
chased from Sigma. The siRNAs targeting hnRNPA1 (target sequence [A],
GAAUGGUUAUAAAAGUGAU; target sequence [B], GGUUCUAUUUGGAAU
UUAU) were purchased from Ambion (Applied Biosystems). The siRNA target-
ingMax (target sequence: CAAAGACAGCUUUCACAGU) was purchased from
Ambion (Applied Biosystems). The control siRNA (Silencer Select Negative
Control #2) was purchased from Ambion (Applied Biosystems). The siRNAs
targeting Rictor (catalog number L-016984-00-0005) and Raptor (catalog
number L-004107-00-0005) were on-TARGETplus SMARTpool siRNAs
(Thermo Scientific, Dharmacon Division). The siRNA targeting Myc was pur-
chased from Ambion (Applied Biosystems) (ID:s9129). The pharmacological
inhibitors used in the study were Akti 1/2 (Calbiochem) at 5 mM, LY294002
(Sigma) at 20 mM, Rapamycin (Sigma) at 2 nM, PP242 (Chemdea) at 2 mM,
Erlotinib (Selleck Chemicals) at 10 mM, and U0126 (Millipore) at 10 mM.Metabolism 17, 1000–1008, June 4, 2013 ª2013 Elsevier Inc. 1005
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Figure 4. Delta Max Promotes Glycolytic Gene Expression and Tumor Growth In Vitro and In Vivo
(A) Proliferation of U87 cells on glucose- or galactose-containingmedia after transfection with empty vector, wild-type (WT) Max, or Delta Max (n = 4; shown is the
mean ± SD; ***p < 0.001).
(B) Relative mRNA transcript levels of GLUT1, GLUT3, HK2, and PDK1 upon acute loss of EGFRvIII with or without Delta Max or wild-type (WT) Max over-
expression (n = 3; shown is the mean ± SD; *p < 0.05; N.S. is nonsignificant).
(legend continued on next page)
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EGFR Mutation-Induced Alternative Splicing of MaxLentiviral Production and Xenograft Tumor Measure
Si RNA sequence targeting Delta Max exon 5 was cloned into pLKO.1-puro
vector (Sigma). A scrambled shRNA (Sigma MISSION shRNA nonmammalian
control [SHC002]) was used as a control. Lentivirus was made using a three-
plasmid packaging system. In brief, shRNAs in the pLKO.1-puro vector were
cotransfected into 293T cells along with expression vectors containing the
vsvg, gag/pol, and rev genes. Forty-eight hours after transfection, lentivirus
was harvested and 8 mg/ml of polybrene was added. Subconfluent U87-
EGFRvIII cells were infected with harvested virus and selected in 0.7 ug/ml
of puromycin for 1 week. Stable cell lines were then used for xenograft tumor
growth study as described above. When tumors were palatable, external
caliper measures were taken over a span of 1 week. For tumor volume the
greatest longitudinal diameter (length) and the greatest transverse diameter
(width) were determined, and tumor volume was calculated by the ellipsoidal
formula (tumor volume = ½ (length 3 width2).Statistical Methods
Tumor volume in the xenograft experiment and cell proliferation on glucose-
and galactose-containing media were compared by two-way ANOVA followed
by Tukey’s multiple comparison’s test using GraphPad Prism 6. For relative
cell growth with hnRNPA1 siRNA, one-way ANOVA followed by Tukey’s
multiple comparison’s test was performed in GraphPad Prism 6. For real-
time quantitative PCR, significance was determined by nonparametric
Mann-Whitney test (one-tailed) (GraphPad Prism 6), and p values < 0.05
were considered significant.ACCESSION NUMBERS
Complete microarray profiles are available at GEO under accession number
GSE46028.SUPPLEMENTAL INFORMATION
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